Abstract
Introduction: Cystic fibrosis (CF) is a severe genetic disorder with a carrier frequency of 1 in 30. In Denmark, prenatal testing is offered when there is a family history of CF or ultrasound anomalies suggest an increased risk of the disease. This study evaluates indications for prenatal CF testing and their outcomes. Methods: Clinical indications and genetic results were analyzed for pregnancies undergoing CF testing in the Central Denmark Region between August 2012 and 2023. The data were categorized according to clinical indication. Results: Among 302 prenatal CF tests, echogenic bowel (EB) was the most frequent (44.7%, N = 135), leading to identification of one CF-affected fetus (0.7%). The second most common indication was EB together with non-CF-associated ultrasound findings (29.5%, N = 89), with no CF-affected fetuses. Known CF predisposition due to family history (15.6%, N = 47) identified five affected fetuses (10.6%) and 25 carriers (53.2%). No CF cases were detected in other included groups (N = 31). Conclusion: These data show that EB has a low positive predictive value for cystic fibrosis in the fetus (1:230) in a country with combined first-trimester screening but no systematic preconception or prenatal screening program for cystic fibrosis. Although the relative risk is increased compared to the general population (1:2,500), EB appears to be a marker of limited clinical utility. In settings without dedicated CF screening strategies, this underscores the importance of considering the most effective allocation of diagnostic resources.
Journal Section:
Prenatal Diagnosis
References
1.
Skov
M
, Baekvad-Hansen
M
, Hougaard
DM
, Skogstrand
K
, Lund
AM
, Pressler
T
, et al. Cystic fibrosis newborn screening in Denmark: experience from the first 2 years
. Pediatr Pulmonol
. 2020
;55
(2
):549
–55
. 2.
Nielsen
OH
, Thomsen
BL
, Green
A
, Andersen
PK
, Hauge
M
, Schiøtz
PO
. Cystic fibrosis in Denmark 1945 to 1985. An analysis of incidence, mortality and influence of centralized treatment on survival
. Acta Paediatr Scand
. 1988
;77
(6
):836
–41
. 3.
Ameratunga
DM
, Said
JM
, Reidy
K
, Palma-Dias
R
. Perinatal outcomes following the ultrasound diagnosis of echogenic bowel: an Australian perspective
. Fetal Diagn Ther
. 2012
;31
(3
):179
–84
. 4.
Bergougnoux
A
, Jouannic
JM
, Verneau
F
, Bienvenu
T
, Gaitch
N
, Raynal
C
, et al. Isolated nonvisualization of the fetal gallbladder should be considered for the prenatal diagnosis of cystic fibrosis
. Fetal Diagn Ther
. 2019
;45
(5
):312
–6
. 5.
Duguépéroux
I
, Scotet
V
, Audrézet
MP
, Saliou
AH
, Collet
M
, Blayau
M
, et al. Nonvisualization of fetal gallbladder increases the risk of cystic fibrosis
. Prenat Diagn
. 2012
;32
(1
):21
–8
. 6.
Mekki
C
, Aissat
A
, Mirlesse
V
, Mayer Lacrosniere
S
, Eche
E
, Le Floch
A
, et al. Prenatal ultrasound suspicion of cystic fibrosis in a multiethnic population: is extensive CFTR genotyping needed
. Genes
. 2021
;12
(5
):670
. 7.
Sundhedsstyrelsen
. Retningslinjer for fosterdiagnostik: prænatal information, risikovurdering, rådgivning og diagnostik – sundhedsstyrelsen [Internet]
; 2020
[cited 2025 Apr 10]. Available from: https://www.sst.dk/da/Udgivelser/2020/Retningslinjer-for-fosterdiagnostik8.
D’Amico
A
, Buca
D
, Rizzo
G
, Khalil
A
, Silvi
C
, Makatsariya
A
, et al. Outcome of fetal echogenic bowel: a systematic review and meta-analysis
. Prenat Diagn
. 2021
;41
(4
):391
–9
. 9.
Wulff
CB
, Gerds
TA
, Rode
L
, Ekelund
CK
, Petersen
OB
, Tabor
A
, et al. Risk of fetal loss associated with invasive testing following combined first-trimester screening for Down syndrome: a national cohort of 147,987 singleton pregnancies
. Ultrasound Obstet Gynecol
. 2016
;47
(1
):38
–44
. 10.
Spinnato
S
, De Biase
A
, Bilardo
CM
, Elvan-Taşpınar
A
. Fetal diagnosis and therapy fetal echogenic bowel: what is real echogenicity? A quantitative method based on histogram analysis of the grayscale
. Fetal Diagn Ther
. 2024
;51
(2
):145
–53
. 11.
Vena
F
, Mazza
A
, Bartolone
M
, Vasta
A
, D’Alberti
E
, Di Mascio
D
, et al. Hyperechogenic fetal bowel: current evidence-based prenatal diagnosis and management
. J Clin Ultrasound
. 2023
;51
(7
):1172
–8
. 12.
Hurt
L
, Wright
M
, Dunstan
F
, Thomas
S
, Brook
F
, Morris
S
, et al. Prevalence of defined ultrasound findings of unknown significance at the second trimester fetal anomaly scan and their association with adverse pregnancy outcomes: the Welsh study of mothers and babies population-based cohort
. Prenat Diagn
. 2016
;36
(1
):40
–8
. 13.
ISUOG
. Echogenic bowel [Internet]
; 2019
[cited 2024 Jul 25]. Available from: https://www.isuog.org/clinical-resources/patient-information-series/patient-information-pregnancy-conditions/abdomen/echogenic-bowel.html14.
Scotchman
E
, Chandler
NJ
, Mellis
R
, Chitty
LS
. Noninvasive prenatal diagnosis of single-gene diseases: the next frontier
. Clin Chem
. 2020
;66
(1
):53
–60
. 15.
Hanson
B
, Scotchman
E
, Chitty
LS
, Chandler
NJ
. Non-invasive prenatal diagnosis (NIPD): how analysis of cell-free DNA in maternal plasma has changed prenatal diagnosis for monogenic disorders
. Clin Sci
. 2022
;136
(22
):1615
–29
. 16.
Jeppesen
LD
, Lildballe
DL
, Hatt
L
, Hedegaard
J
, Singh
R
, Toft
CLF
, et al. Noninvasive prenatal screening for cystic fibrosis using circulating trophoblasts: detection of the 50 most common disease-causing variants
. Prenat Diagn
. 2023
;43
(1
):3
–13
. 17.
Chandler
NJ
, Ahlfors
H
, Drury
S
, Mellis
R
, Hill
M
, McKay
FJ
, et al. Noninvasive prenatal diagnosis for cystic fibrosis: implementation, uptake, outcome, and implications
. Clin Chem
. 2020
;66
(1
):207
–16
. 18.
Toft
CLF
, Diemer
T
, Ingerslev
HJ
, Pedersen
IS
, Adrian
SW
, Kesmodel
US
. Patients’ choices and opinions on chorionic villous sampling and non-invasive alternatives for prenatal testing following preimplantation genetic testing for hereditary disorders: a cross-sectional questionnaire study
. Prenat Diagn
. 2022
;42
(2
):212
–25
. 19.
Romero
S
, Biggio
JR
, Saller
DN
, Giardine
R
. Carrier screening genetic conditions: committee opinion number 691
; 2017
.20.
Archibald
AD
, McClaren
BJ
, Caruana
J
, Tutty
E
, King
EA
, Halliday
JL
, et al. The Australian reproductive genetic carrier screening project (Mackenzie’s Mission): design and Implementation
. J Pers Med
. 2022
;12
(11
):1781
. 21.
Archibald
AD
, Smith
MJ
, Burgess
T
, Scarff
KL
, Elliott
J
, Hunt
CE
, et al. Reproductive genetic carrier screening for cystic fibrosis, fragile X syndrome, and spinal muscular atrophy in Australia: outcomes of 12,000 tests
. Genet Med
. 2018
;20
(5
):513
–23
. 22.
Singer
A
, Sagi-Dain
L
. Impact of a national genetic carrier-screening program for reproductive purposes
. Acta Obstet Gynecol Scand
. 2020
;99
(6
):802
–8
. 23.
Rosenfeld
M
, Wainwright
CE
, Higgins
M
, Wang
LT
, McKee
C
, Campbell
D
, et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
. Lancet Respir Med
. 2018
;6
(7
):545
–53
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
